Next Generation Cancer Protection: The Bivalent HPV Vaccine for Females

Table 4

Cross protection offered by Cervarix [66].

Endpoint	Population	Vaccine efficacy (96.1% CI)	Average time of follow-up
6 month persistent infection	TVC-N
HPV 31		77% (67, 84)	44 month
HPV 33		43% (19, 60)	44 month
HPV 45		79% (61, 89)	44 month
CIN 2+ associated with	TVC-N
HPV 31		89% (66, 98)	44 month
HPV 33		82% (53, 95)	44 month
HPV 45		100% (42, 100)	44 month
Regardless of HPV type	TVC-N	93% (79, 99)	44 months

Infection definitions: 6-month definition required the detection of the same HPV type in two consecutive cervical samples, with no negative sample in between, over a minimum of 5 months.
CIN 2+ means cervical intraepithelial neoplasia grades 2 and 3 and adenocarcinoma insitu. Lesions may be coinfected with HPV 16/18.
TVC means total vaccinated cohort: women with at least one injection, seropositive or negative, PCR positive or negative for one or more HPV types at baseline, regardless of Pap result; case counting starting first day after first injection.
TVC-N means TVC naive: women who received ≥1 vaccine dose with normal cytology, seronegative for HPV-16/18 and DNA-negative for 14 oncogenic HPV types at baseline (16, 18, 31. 33, 35, 39, 45, 51, 52, 56, 58, 59, 66, and 68); case counting starting first day after first injection. Subjects were followed for an average 44.3 months after first injection.